Doxorubicin-based chemotherapy is currently the most frequently used treatment for triple negative breast cancer (TNBC), yet the response rate is not high due to the lack of a biomarker allowing identification of responsive patients before the chemotherapy is initiated. | CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy